Reverse cholesterol transport and hepatic osteodystrophy.
Cell Metab
; 34(3): 347-349, 2022 03 01.
Article
em En
| MEDLINE
| ID: mdl-35235770
ABSTRACT
In this issue of Cell Metabolism, Lu et al. show that chronic liver disease increases the expression and activity of PP2Ac, a phosphatase that downregulates the excretion of lecithin-cholesterol aceyltransferase (LCAT). LCAT, a liver-derived enzyme, protects bone and prevents bone loss, and its lowered levels in progressive liver injury cause hepatic osteodystrophy (HOD) and worsen liver fibrosis. These discoveries open the possibility that recombinant LCAT may be a treatment for both HOD and liver fibrosis.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Colesterol
/
Fosfatidilcolina-Esterol O-Aciltransferase
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article